Stefanie J. Millar

1.3k total citations
30 papers, 910 citations indexed

About

Stefanie J. Millar is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Physiology. According to data from OpenAlex, Stefanie J. Millar has authored 30 papers receiving a total of 910 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 6 papers in Epidemiology and 4 papers in Physiology. Recurrent topics in Stefanie J. Millar's work include Cystic Fibrosis Research Advances (24 papers), Neonatal Respiratory Health Research (11 papers) and Tracheal and airway disorders (9 papers). Stefanie J. Millar is often cited by papers focused on Cystic Fibrosis Research Advances (24 papers), Neonatal Respiratory Health Research (11 papers) and Tracheal and airway disorders (9 papers). Stefanie J. Millar collaborates with scholars based in United States, Ireland and Germany. Stefanie J. Millar's co-authors include Michael W. Konstan, David J. Pasta, Gregory S. Sawicki, Jeffrey S. Wagener, Wayne J. Morgan, Edward F. McKone, Ashley Yegin, Charles A. Johnson, Clement L. Ren and Donald R. VanDevanter and has published in prestigious journals such as Blood, American Journal of Respiratory and Critical Care Medicine and The Journal of Pediatrics.

In The Last Decade

Stefanie J. Millar

30 papers receiving 895 citations

Peers

Stefanie J. Millar
Simon Tian United States
Donatello Salvatore Italy
Alicia Padilla‐Galo Spain
Jonathan McCormick United Kingdom
Carol Brunzell United States
Olga E.M. Savenije Netherlands
Sung Jun Chung South Korea
C Wharton Australia
Evelien R. van Meel Netherlands
Shivanthan Shanthikumar Australia
Simon Tian United States
Stefanie J. Millar
Citations per year, relative to Stefanie J. Millar Stefanie J. Millar (= 1×) peers Simon Tian

Countries citing papers authored by Stefanie J. Millar

Since Specialization
Citations

This map shows the geographic impact of Stefanie J. Millar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefanie J. Millar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefanie J. Millar more than expected).

Fields of papers citing papers by Stefanie J. Millar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefanie J. Millar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefanie J. Millar. The network helps show where Stefanie J. Millar may publish in the future.

Co-authorship network of co-authors of Stefanie J. Millar

This figure shows the co-authorship network connecting the top 25 collaborators of Stefanie J. Millar. A scholar is included among the top collaborators of Stefanie J. Millar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefanie J. Millar. Stefanie J. Millar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Brownlee, Wallace, Aiden Haghikia, Brooke Hayward, et al.. (2023). Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study. Multiple Sclerosis and Related Disorders. 76. 104791–104791. 4 indexed citations
3.
Lee, Tim, Gregory S. Sawicki, Josje Altenburg, et al.. (2022). EFFECT OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR ON ANNUAL RATE OF LUNG FUNCTION DECLINE IN PEOPLE WITH CYSTIC FIBROSIS. Journal of Cystic Fibrosis. 22(3). 402–406. 36 indexed citations
4.
Sawicki, Gregory S., Michael W. Konstan, Edward F. McKone, et al.. (2022). Rate of Lung Function Decline in People with Cystic Fibrosis Having a Residual Function Gene Mutation. Pulmonary Therapy. 8(4). 385–395. 3 indexed citations
5.
Arteaga‐Solis, Emilio, et al.. (2021). Burden of cystic fibrosis in children <12 years of age prior to the introduction of CFTR modulator therapies. BMJ Open Respiratory Research. 8(1). e000998–e000998. 6 indexed citations
6.
Sawicki, Gregory S., et al.. (2021). Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation. Journal of Cystic Fibrosis. 21(1). 96–103. 8 indexed citations
7.
Dasenbrook, Elliott C., Aliza K. Fink, Michael S. Schechter, et al.. (2019). Rapid lung function decline in adults with early-stage cystic fibrosis lung disease. Journal of Cystic Fibrosis. 19(4). 527–533. 2 indexed citations
8.
Wagener, Jeffrey S., Donald R. VanDevanter, Michael W. Konstan, et al.. (2019). Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis. Pediatric Pulmonology. 55(3). 828–834. 21 indexed citations
9.
Wagener, Jeffrey S., Michael Williams, Stefanie J. Millar, et al.. (2018). Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis. Journal of Cystic Fibrosis. 17(4). 496–502. 11 indexed citations
10.
Wagener, Jeffrey S., Stefanie J. Millar, Nicole Mayer-Hamblett, et al.. (2017). Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation. Journal of Cystic Fibrosis. 17(4). 503–510. 13 indexed citations
11.
Morgan, Wayne J., Jeffrey S. Wagener, David J. Pasta, et al.. (2017). Relationship of Antibiotic Treatment to Recovery after Acute FEV1 Decline in Children with Cystic Fibrosis. Annals of the American Thoracic Society. 14(6). 937–942. 29 indexed citations
12.
Konstan, Michael W., Edward F. McKone, Richard B. Moss, et al.. (2016). Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. The Lancet Respiratory Medicine. 5(2). 107–118. 213 indexed citations
13.
Sawicki, Gregory S., Edward F. McKone, David J. Pasta, et al.. (2015). Sustained Benefit from Ivacaftor Demonstrated by Combining Clinical Trial and Cystic Fibrosis Patient Registry Data. American Journal of Respiratory and Critical Care Medicine. 192(7). 836–842. 168 indexed citations
14.
Sawicki, Gregory S., Clement L. Ren, Michael W. Konstan, et al.. (2013). Treatment complexity in cystic fibrosis: Trends over time and associations with site-specific outcomes. Journal of Cystic Fibrosis. 12(5). 461–467. 116 indexed citations
15.
Morgan, Wayne J., Jeffrey S. Wagener, Ashley Yegin, et al.. (2013). Probability of Treatment Following Acute Decline in Lung Function in Children with Cystic Fibrosis is Related to Baseline Pulmonary Function. The Journal of Pediatrics. 163(4). 1152–1157.e2. 34 indexed citations
16.
17.
VanDevanter, Donald R., Ashley Yegin, Wayne J. Morgan, et al.. (2011). Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint. Journal of Cystic Fibrosis. 10(6). 453–459. 27 indexed citations
18.
Schechter, Michael S., Susanna A. McColley, Warren E. Regelmann, et al.. (2011). Socioeconomic Status and the Likelihood of Antibiotic Treatment for Signs and Symptoms of Pulmonary Exacerbation in Children with Cystic Fibrosis. The Journal of Pediatrics. 159(5). 819–824.e1. 29 indexed citations
19.
Konstan, Michael W., Jeffrey S. Wagener, David J. Pasta, et al.. (2011). Clinical use of dornase alfa is associated with a slower rate of FEV1 decline in cystic fibrosis. Pediatric Pulmonology. 46(6). 545–553. 67 indexed citations
20.
Konstan, Michael W., Jeffrey S. Wagener, Ashley Yegin, et al.. (2010). Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint. Journal of Cystic Fibrosis. 9(5). 332–338. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Simon Tian Breakdown of academic impact, for papers by Donatello Salvatore Breakdown of academic impact, for papers by Alicia Padilla‐Galo Breakdown of academic impact, for papers by Jonathan McCormick Breakdown of academic impact, for papers by Carol Brunzell Breakdown of academic impact, for papers by Olga E.M. Savenije Breakdown of academic impact, for papers by Sung Jun Chung Breakdown of academic impact, for papers by C Wharton Breakdown of academic impact, for papers by Evelien R. van Meel Breakdown of academic impact, for papers by Shivanthan Shanthikumar
Rankless by CCL
2026